SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Trial Details

NCT ID
NCT06323239
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • SBRT
  • Low-dose Radiotherapy (LDRT)
  • Toripalimab
  • Gemcitabine
  • Cisplatin
  • IMRT
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Diagnosed as recurrence/metastatic NPC
  • Histopathological diagnosis of NPC(WHO II/III)
  • ECOG 0-1 point
  • No treatment to r/mNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →